Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
48.12
-0.66 (-1.35%)
At close: Sep 17, 2025, 4:00 PM EDT
50.99
+2.87 (5.96%)
Pre-market: Sep 18, 2025, 7:13 AM EDT
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Kymera Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $59.56, which forecasts a 23.77% increase in the stock price over the next year. The lowest target is $44 and the highest is $79.
Price Target: $59.56 (+23.77%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 7 | 7 | 7 | 7 |
| Buy | 5 | 6 | 7 | 7 | 7 | 8 |
| Hold | 3 | 4 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $60 | Buy | Initiates | $60 | +24.69% | Sep 17, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $70 | Buy | Initiates | $70 | +45.47% | Sep 16, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $56 → $53 | Buy | Maintains | $56 → $53 | +10.14% | Jun 27, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $57 → $53 | Buy | Maintains | $57 → $53 | +10.14% | Jun 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $60 | Strong Buy | Maintains | $54 → $60 | +24.69% | Jun 26, 2025 |
Financial Forecast
Revenue This Year
77.08M
from 47.07M
Increased by 63.75%
Revenue Next Year
57.41M
from 77.08M
Decreased by -25.53%
EPS This Year
-3.48
from -2.98
EPS Next Year
-4.18
from -3.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 154.3M | 113.7M | |||
| Avg | 77.1M | 57.4M | |||
| Low | 42.7M | 13.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 227.9% | 47.5% | |||
| Avg | 63.8% | -25.5% | |||
| Low | -9.3% | -82.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.60 | -3.29 | |||
| Avg | -3.48 | -4.18 | |||
| Low | -3.84 | -6.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.